A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA UNDER THE GADOLINIUM CONCENTRATION-TIME CURVE (IAUGC)

Lawrence Cher, Anna Nowak, George Iatropoulos, Weon Sup Lee, Seon Young Lee, Sang Ryeol Shim, Jin San Yoo

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Pages (from-to)17-17
Number of pages1
JournalNeuro-Oncology
Volume19
Publication statusPublished - Nov 2017
Event22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology - San Francisco, United States
Duration: 16 Nov 201719 Nov 2017

Cite this